PolyPid Sets Virtual Investor Day to Unveil 2030 Strategy, Diabetic Foot Infection Candidate
Event summary
- PolyPid to host Virtual Investor Day on October 28, 2026, to outline 'PolyPid 2030' long-term strategy.
- Management to provide update on D-PLEX₁₀₀ NDA under FDA Priority Review with PDUFA goal date of November 28, 2026.
- Introduction of PD01B, a new product candidate for diabetic foot infections, based on Kynatrix™ delivery technology.
- Event to feature Key Opinion Leader Warren S. Joseph, DPM, FIDSA, discussing diabetic foot infections and treatment approaches.
The big picture
PolyPid's Investor Day comes as the biopharmaceutical sector increasingly focuses on long-acting, controlled-release drugs. The company's strategic update and new product introduction aim to address critical unmet medical needs in surgical care and metabolic diseases. The FDA's Priority Review designation for D-PLEX₁₀₀ underscores the regulatory significance of the company's lead product candidate.
What we're watching
- Regulatory Timeline
- Whether the FDA will meet the November 28, 2026 PDUFA goal date for D-PLEX₁₀₀ approval.
- Pipeline Expansion
- The pace at which PD01B advances through development for diabetic foot infections.
- Market Positioning
- How PolyPid 2030 strategy positions the company against competitors in surgical site infection prevention.
Related topics